A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Placebo tablets match with that of orelabrutinib (ICP-022) tablets in appearanceshapesizeand weight.Orelabrutinib
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
Time to onset of confirmed disability progression (CDP) events, confirmed over at least 24 weeks (24-week CDP).
Endpoint detail
1) Time to onset of CDP events on EDSS, confirmed over at least 12 weeks (12-week CDP), 2) The total number of new or enlarging T2 lesions on MRI scans of the brain
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.